<DOC>
	<DOCNO>NCT00006392</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development cancer . It yet know regimen selenium and/or vitamin E may effective prevent prostate cancer . PURPOSE : Randomized phase III trial determine effectiveness selenium vitamin E , either alone together , prevent prostate cancer .</brief_summary>
	<brief_title>S0000 Selenium Vitamin E Preventing Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect selenium vitamin E administer alone vs combination clinical incidence prostate cancer . - Compare effect prevention regimens incidence lung cancer , colorectal cancer , cancer combine participant study . - Compare effect prevention regimens prostate cancer-free survival , lung cancer-free survival , colorectal cancer-free survival , cancer-free survival , overall survival , serious cardiovascular event participant .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Healthy male volunteer Digital rectal examination ( DRE ) deem suspicious prostate cancer perform within 364 day prior study entry Participants suspicious DRE ineligible even recent subsequent biopsy negative cancer Total prostatespecific antigen ≤ 4.0 ng/mL within 364 day prior study entry No prior prostate cancer highgrade ( grade 23 ) prostatic intraepithelial neoplasia PATIENT CHARACTERISTICS : Age : See Disease Characteristics Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Cardiovascular : Systolic blood pressure &lt; 160 mm Hg Diastolic blood pressure &lt; 90 mm Hg No history hemorrhagic stroke Other : No malignancy within past 5 year except basal cell squamous cell skin cancer No uncontrolled medical illness No retinitis pigmentosa PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other At least 7 year since prior randomization SWOG9217 , completion endofstudy biopsy requirement No additional concurrent selenium vitamin E ( contain individual supplement , antioxidant mix , multivitamin ) Concurrent multivitamin allow ( supply study ) No concurrent anticoagulation therapy ( e.g. , warfarin ) Concurrent prophylactic aspirin ( average daily dose great 175 mg/day ) allow Concurrent daily aspirin dose ≤ 81 mg participant receive clopidogrel Concurrent antihypertension medication allow No concurrent participation another study involve medical , surgical , nutritional , lifestyle intervention ( unless longer receive intervention followup phase )</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>prostate cancer</keyword>
</DOC>